{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tositumomab+and+Iodine+I+131+Tositumomab",
    "query": {
      "intervention": "Tositumomab and Iodine I 131 Tositumomab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tositumomab+and+Iodine+I+131+Tositumomab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T10:42:52.810Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00319332",
      "title": "A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma, Small Cleaved-Cell, Follicular",
        "Lymphoma, Large-Cell, Follicular",
        "Lymphoma, Follicular",
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Ibritumomab Tiuxetan",
          "type": "DRUG"
        },
        {
          "name": "Iodine I 131 Tositumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2005-09",
      "completion_date": "2021-02",
      "has_results": false,
      "last_update_posted_date": "2015-04-17",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 8,
      "location_summary": "Iowa City, Iowa • St Louis, Missouri • Buffalo, New York + 5 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Charleston",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00319332"
    },
    {
      "nct_id": "NCT00434629",
      "title": "Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Lymphoma",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bexxar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2007-02",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2016-08-17",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00434629"
    },
    {
      "nct_id": "NCT00475332",
      "title": "Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Iodine I -01 Tositumomab (Bexxar)",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2007-09",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2012-02-15",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00475332"
    },
    {
      "nct_id": "NCT00022906",
      "title": "Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Iodine-131 Anti-B1 Antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corixa Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "1999-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022906"
    },
    {
      "nct_id": "NCT00022958",
      "title": "Expanded Access Study of Iodine-131 Anti-B1 Antibody",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Iodine-131 Anti-B1 Antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corixa Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 1,
      "location_summary": "South San Francisco, California",
      "locations": [
        {
          "city": "South San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022958"
    },
    {
      "nct_id": "NCT00073918",
      "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "iodine I 131 tositumomab",
          "type": "RADIATION"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 111,
      "start_date": "1999-02",
      "completion_date": "2011-10-02",
      "has_results": true,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073918"
    },
    {
      "nct_id": "NCT01484093",
      "title": "Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 96,
      "start_date": "2011-11-29",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-08-16",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        },
        {
          "city": "Sleepy Hollow",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01484093"
    },
    {
      "nct_id": "NCT00022945",
      "title": "Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Iodine-131 Anti-B1 Antibody",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corixa Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022945"
    },
    {
      "nct_id": "NCT00476047",
      "title": "Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoid Leukemia in Remission",
        "Stage I Chronic Lymphocytic Leukemia",
        "Stage II Chronic Lymphocytic Leukemia",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tositumomab and Iodine I 131 Tositumomab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-02",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2017-10-12",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00476047"
    },
    {
      "nct_id": "NCT00268983",
      "title": "Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Tositumomab and Iodine I 131 Tositumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2004-10",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-10-09T10:42:52.810Z",
      "location_count": 1,
      "location_summary": "Walla Walla, Washington",
      "locations": [
        {
          "city": "Walla Walla",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00268983"
    }
  ]
}